During the past 20 years InSight has developed a wide portfolio of Biosimilars manufacturing technologies and products.

Multiple “first generation” off-patent products were developed and commercialized by InSight over the years:

  • Interferon alpha (2a)
  • Interferon alpha (2b)
  • Interferon beta-1a
  • Interferon beta-1b
  • EPO
  • G-CSF
  • GM-CSF
  • HGH
  • FSH

In addition, technologies for the manufacturing of several “second generation” Biosimilars have been commercialized:

  • Rituximab
  • Etanercept
  • Trastuzumab

Currently, different products are manufactured at our GMP facility and our pipeline includes post 2020, “third generation” products in development.